Its nutrition profile is 34% protein, 17% fat, 3% fiber, and 399 kcal/cup
launch expected April Coordinated global commercialization My takeaway 1 Obesity drugs = new pharma battleground This is now a head-to-head innovation race, not just market expansion 2 Small efficacy differences = huge market impact Even a few percentage points shift prescribing behavior + billions in revenue 3 Lifecycle management is critical Higher doses, new pens, expanded indications = defending blockbuster franchises 4 Broader implication Expect continued competition across: GLP-1 / incretin space Combination therapies Next-gen metabolic drugs #Pharma #Obesity #GLP1 #NovoNordisk #EliLilly #DrugDevelopment #HealthcareInnovation To view or add a comment, sign in Eli Lilly and Company's orforglipron target raised by Wolfe analyst amid strong market potential orforglipron Eli Lilly obesity Wolfe analyst has raised the price target for Eli Lilly from $1250 to $1325, citing strong long-term demand for its experimental oral obesity drug, orforglipron
GLP-1 (glucagon-like peptide-1) is a naturally occurring hormone that helps regulate appetite and blood sugar
It is a synthetic blueprint of the protein exendin-4, isolated from the Gila monster's venom
Changes in albuminuria predict cardiovascular and renal outcomes in type 2 diabetes: a post hoc analysis of the LEADER trial
Therefore, it is clinically necessary to find an appropriate balance point that alleviates inflammation caused by iron overload without impairing normal iron function or inducing adverse effects
